Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.59 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 2/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | PGR | P06401 | 4/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | TDP2 | O95551 | 2/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31491189 | 0.88 | TAAR1 (0.71) | TAAR1ALOX5MAOBESR2PGR | |
| SCHEMBL16394285 | 0.88 | TAAR1 (0.71) | TAAR1ALOX5MAOBESR2PGR | |
| SCHEMBL20669453 | 0.85 | TAAR1 (0.68) | TAAR1ALOX5MAOBESR2PGR | |
| SCHEMBL2088470 | 0.84 | ALOX5 (0.52) | TAAR1ALOX5MAOBESR2PGR | |
| SCHEMBL16394095 | 0.83 | TAAR1 (0.65) | TAAR1ALOX5MAOBESR2PGR | |
| SCHEMBL29776911 | 0.83 | TAAR1 (0.65) | TAAR1ALOX5MAOBESR2PGR | |
| SCHEMBL1520884 | 0.83 | TAAR1 (0.65) | TAAR1ALOX5MAOBESR2PGR | |
| SCHEMBL817554 | 0.83 | ALOX5 (0.65) | TAAR1ALOX5MAOBESR2PGR | |
| SCHEMBL31222672 | 0.83 | ALOX5 (0.65) | TAAR1ALOX5MAOBESR2PGR | |
| SCHEMBL22167038 | 0.81 | TAAR1 (0.63) | TAAR1ALOX5MAOBESR2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651900-A1 | NEPRILYSIN INHIBITORS | Theravance, Inc. (US) | 2013-10-23 | — | — | EP | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| WO-2012082857-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| WO-2005016883-A2 | ACRYLAMIDE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF | ICOS CORPORATION (US) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | TAAR1 364/4885ALOX5 3374/4885MAOB 2140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.